Table 2.
Vitamin D related gene polymorphisms in AD patients and controls.
| Genotype | AD | Control | Crude OR (95% CI) | p | Adjusted OR (95% CI)b | pb |
|---|---|---|---|---|---|---|
| rs2282679A>C | ||||||
| AA/AC/CC | 341/279/56 | 245/250/56 | NA | 0.099a | NA | NA |
| Additive | 0.829 (0.697–0.987) | 0.035 | 0.827 (0.694–0.985) | 0.034 | ||
| Dominant (AA/AC+CC) | 341/335 | 245/306 | 0.787 (0.628-0.986) | 0.037 | 0.780 (0.621–0.980) | 0.033 |
| Recessive (AA+AC/CC) | 620/56 | 295/56 | 0.798 (0.541–1.178) | 0.256 | 0.806 (0.545–1.193) | 0.282 |
| rs10741657T>C | ||||||
| TT/TC/CC | 100/290/286 | 69/228/254 | NA | 0.318a | NA | NA |
| Additive | 0.882 (0.751–1.038) | 0.130 | 0.888 (0.754–1.046) | 0.154 | ||
| Dominant (TT/TC+CC) | 100/576 | 69/482 | 0.825 (0.593–1.147) | 0.252 | 0.830 (0.596–1.158) | 0.273 |
| Recessive (TT+TC/CC) | 390/286 | 297/254 | 0.857 (0.684–1.076) | 0.184 | 0.865 (0.688–1.087) | 0.214 |
| rs12785878T>G | ||||||
| TT/TG/GG | 134/335/207 | 127/271/153 | NA | 0.311a | NA | NA |
| Additive | 1.130 (0.963–1.325) | 0.134 | 1.109 (0.944–1.303) | 0.208 | ||
| Dominant (TT/TG+GG) | 134/542 | 127/424 | 1.212 (0.921–1.593) | 0.170 | 1.162 (0.881–1.532) | 0.289 |
| Recessive (TT+TG/GG) | 469/207 | 398/153 | 1.148 (0.896–1.471) | 0.275 | 1.137 (0.885–1.460) | 0.316 |
| rs6013897T>A | ||||||
| TT/TA/AA | 471/185/20 | 370/167/14 | NA | 0.499a | NA | NA |
| Additive | 0.928 (0.751–1.147) | 0.489 | 0.923 (0.745–1.143) | 0.462 | ||
| Dominant (TT/TA+AA) | 471/205 | 370/181 | 0.890 (0.699–1.133) | 0.344 | 0.882 (0.691–1.126) | 0.313 |
| Recessive (TT+TA/AA) | 656/20 | 537/14 | 1.169 (0.585–2.337) | 0.658 | 1.186 (0.590–2.383) | 0.632 |
AD, Alzheimer's disease; OR, odds ratio; CI, confidence interval.
a
Chi-Square test for genotype distributions between AD patients and controls.
b
Adjusted for age and sex.